3 New Strong Buy Ratings from Top-Rated Analysts: 08/19/2026

Here’s a peek at the latest picks from our Strong Buy Stocks from Top Wall Street Analysts screener:

• RCM Technologies (NASDAQ: RCMT) just crushed earnings with more good stuff ahead
• Phibro Animal Health (NASDAQ: PAHC) could be an excellent dip buy 
• SK Hynix (NASDAQ: SKHY) has analysts calling for nearly 100% upside

P.S. Get more alerts like this daily … Try WallStreetZen Premium.

A note from our sponsors...

1. RCM Technologies (NASDAQ: RCMT)

This technology services company recently posted impressive Q2 results, showcasing improved operational leverage and strong momentum in its Engineering Services business, positioning it well for continued growth heading into the second half of 2026.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $40.11 — get current quote

Why we're watching:

• RCMT only has one recommendation at the moment, but it’s a bullish Strong Buy. Stay updated on future recommendations here
• That recommendation comes from Benchmark researcher Bill Sutherland (a top 12% rated analyst), who cites the company's operational leverage improvements and optimism around Engineering Services, though he remains cautious on Life Sciences' FY 2026 recovery. 
• Note: A small pool of coverage isn’t necessarily a bad thing. Often, if the stock has solid fundamentals like this one, this is an indication of an under-the-radar pick that simply has not been discovered yet.
• And this stock IS strong fundamentally. Q2 earnings demonstrated execution strength: EPS of $0.77 beat with 57.1% year-over-year growth, while revenue of $86.5M exceeded with 12.4% YoY growth.
• Industry ranking context: RCMT is currently the #1 highest-rated stock in the Conglomerate industry, which has an Industry Rating of C.
• Zen Ratings highlights: RCMT earns an overall A rating, which amounts to a Strong Buy recommendation. Stocks with this rating represent the elite top 5% of all stocks tracked based on a rigorous 115-factor fundamental review.
• Component Grades: RCMT shines across multiple dimensions with As for Financials, Sentiment, and Value, reflecting strong fundamentals, positive analyst perception, and attractive valuation, while maintaining solid Bs for Growth and Safety, a combination that supports its top industry ranking. See all 7 Component Grades here

2. Phibro Animal Health (NASDAQ: PAHC)

Phibro Animal Health operates as a global entity focused on the research, production, and supply of animal health and mineral nutrition solutions serving the agricultural and veterinary markets. Trading well below its 52-week high and boasting strong value metrics, the company presents a compelling turnaround opportunity in the pharmaceutical space.

Zen Rating: B (Buy) — see full analysis

Recent Price: $34.38 — get current quote

Max 1-year forecast: $44.00

Why we're watching:

• Analyst coverage isn’t PAHC’s strong suit, with only 1 covering analyst. However, it is often the case with under-the-radar plays like this that coverage comes after the momentum picks up. Let’s look below to see why PAHC has potential. (And if you want: See all recommendations here)
• It appears undervalued: PAHC is trading at a PEG under 1 (anything under 1.5 is considered a bargain) — yet with 10 earnings beats under its belt, it screams “undervalued.” 
• Industry ranking context: PAHC is currently the #12 highest-rated stock in the Pharmaceutical industry, which has an Industry Rating of B.
• Zen Ratings highlights: PAHC earns an overall B rating, representing a Buy recommendation. This tier represents the top 20% of stocks tracked based on a careful 115-factor fundamental analysis.
• Component Grades: PAHC excels with an A for Value, reflecting the stock's attractive valuation relative to earnings and growth potential, positioning it well for appreciation as fundamentals improve. See all 7 Component Grades here

3. SK Hynix (NASDAQ: SKHY)

One of the world's largest memory semiconductor companies! With the memory sector rebounding and AI-driven demand surging, the company stands at the forefront of a powerful cyclical recovery.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $165.44 — get current quote

Max 1-year forecast: $320.00

Why we're watching:

• SKHY has solid, bullish coverage among the analysts we track, with 5 Strong Buy and 4 Buy recommendations. See all recommendations here
• For example, Rosenblatt researcher Kevin Cassidy (a top 1% rated analyst) recently initiated coverage with a Strong Buy rating and a price target suggesting the stock could see nearly 100% upside in the coming year. 
• Likewise, Cantor Fitzgerald researcher C.J. Muse (a top 1% rated analyst) initiated coverage with a Strong Buy and a price target suggesting the stock could see over 80% upside. 
• Four additional top 1% analysts cover the stock — and they all express bullish views on the memory sector's expansion.
• Industry ranking context: SKHY is currently the #1 highest-rated stock in the Semiconductor industry, which has an Industry Rating of A.
• Zen Ratings highlights: SKHY earns an overall A rating, which is equal to a Strong Buy recommendation. Stocks in this topmost tier have historically delivered nearly 30% annual returns, soundly beating the S&P.
• Component Grades: SKHY excels with strong As for Value, Sentiment, and Financials, demonstrating that the company combines attractive valuation with robust fundamentals and positive market sentiment during this memory upcycle. See all 7 Component Grades here

What to Do Next?

• 77 Best Stocks NOW! >
• Options Trading with the Zen Ratings >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.